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Abstract
Coronavirus disease 2019 (COVID‐19) has had different waves within the same
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country. The spread rate and severity showed different properties within the
COVID‐19 different waves. The present work aims to compare the spread and the
severity of the different waves using the available data of confirmed COVID‐19
cases and death cases. Real‐data sets collected from the Johns Hopkins University
Center for Systems Science were used to perform a comparative study between
COVID‐19 different waves in 12 countries with the highest total performed tests for
severe acute respiratory syndrome coronavirus 2 detection in the world (Italy, Brazil,
Japan, Germany, Spain, India, USA, UAE, Poland, Colombia, Turkey, and Switzerland).
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The total number of confirmed cases and death cases in different waves of

7

number of confirmed cases for the same periods. In all the selected 12 countries,

6

Department of Clinical Pharmacy, Faculty of
Pharmacy, Nahda University, Beni‐Suef, Egypt
8

Department of Clinical Pharmacy,
Ophthalmology hospital – El Minia, El Minia,
Egypt
Correspondence
Mohamed E. A. Abdelrahim, Department of
Clinical Pharmacy, Faculty of Pharmacy,
Beni‐Suef University, Beni‐Suef, Egypt.
Email: mohamedemam9@yahoo.com

COVID‐19 were compared to that of the previous one for equivalent periods. The
total number of death cases in each wave was presented as a percentage of the total
Wave 2 had a much higher number of confirmed cases than that in Wave 1.
However, the death cases increase was not comparable with that of the confirmed
cases to the extent that some countries had lower death cases than in Wave 1, UAE,
and Spain. The death cases as a percentage of the total number of confirmed cases in
Wave 1 were much higher than that in Wave 2. Some countries have had Waves 3
and 4. Waves 3 and 4 have had lower confirmed cases than Wave 2, however, the
death cases were variable in different countries. The death cases in Waves 3 and 4
were similar to or higher than Wave 2 in most countries. Wave 2 of COVID‐19 had a
much higher spread rate but much lower severity resulting in a lower death rate in
Wave 2 compared with that of the first wave. Waves 3 and 4 have had lower
confirmed cases than Wave 2; that could be due to the presence of appropriate
treatment and vaccination. However, that was not reflected in the death cases,
which were similar to or higher than Wave 2 in most countries. Further studies are
needed to explain these findings.
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| INTRODUCTION

ET AL.

(CSSE) at Johns Hopkins University (JHU).20 The COVID‐19 time
series data for the 12 countries were downloaded for the period of

The first wave of coronavirus disease‐2019 (COVID‐19) started at

January 22, 2020–July 24, 2021, from the Johns Hopkins University

the end of 2019 in Wuhan, China.1,2 The spread of the disease in the

Center for Systems Science and Engineering (JHU CSSE) as shown in

first wave was rapid and affected more than 200 countries around

Table 1.20 The outlier observations and the negative values were

the world. The route of severe acute respiratory syndrome

removed from the time series data as shown in Table 1.

coronavirus 2 (SARS‐CoV‐2) spread facilitates its spread between

From that date, the total number of cases and death cases in

people as it is transmitted through droplets after sneezing or

COVID‐19 Wave 2 was compared with that of Wave 1 for equivalent

coughing of the infected subjects and also through contaminated

periods. If the country has Wave 3, it was compared to Wave 2 and if

fomites.3 The rate of COVID‐19 spread was higher in Europe and the

it has Wave 4 it was compared to Wave 3, and so on. Each wave's

USA while it was lower in Africa.

4,5

Many factors could influence the

spread of the disease or its severity as discussed by previous studies

total number of death cases was presented as a percentage of the
total number of confirmed cases for equivalent periods.

such as country average age and weather temperatures, antimalarial
administration, and Bacillus Calmette–Guérin (BCG) vaccine.4–6 In
addition to the spread rate of the disease, the severity of infection

3 |
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was also different from one country to another ranging from about
4% mortality rate in China to about 15% in Italy.4,7 Most COVID‐19

Comparison of the total number of confirmed cases and death cases

cases are mild cases that do not require hospital admission; only

in COVID‐19 different wave and the one before it for equivalent

home quarantine with the administration of the treatment protocol

periods are shown in Table 2. In all the selected 12 countries, Wave 2

and awareness of the quarantine protocol could be enough to cure

had a much higher number of confirmed cases ranged from 1.5 to

the patients and prevent any possible infection.1,2,8–10 It was pre-

35.7 times than in Wave 1 as shown in Table 2. However, the in-

dicted that the pattern of COVID‐19 spread would be similar to that

crease in the estimated COVID‐19 deaths in Wave 2 compared with

of the previous influenza pandemic in 1918 and the infection rate will

Wave 1 had a lower magnitude compared with that of the confirmed

rise again forming the second and third waves of pandemic spread.11

cases to the extent that in some countries the total number of death

The influenza pandemic of 1918–1920 is recognized to take place in

cases in Wave 2 was lower than that in Wave 1 (UAE and Spain) as

three waves, each with a different spread and severity, starting in the

shown in Table 3. Some countries had Waves 3 and 4, in which

12–15

Several studies used artificial in-

Waves 3 and 4 had lower confirmed cases than Wave 2; however,

telligence models to predict the first COVID‐19 wave spread rate,

the death cases in Waves 3 and 4 were variable in different countries.

diagnosis, treatment, and mortality rate for most of the affected

The death cases in Waves 3 and 4 were similar to or higher than

spring and summer of 1918.

countries.

16–18

Currently, the world is suffering from the second and

Wave 2 in most countries.

third waves of COVID‐19 and in some countries the fourth wave. The

The total number of death cases in each wave as a percentage of

spread rate and severity of the COVID‐19 second and third waves

the total number of confirmed cases for the equivalent period is

are different from that of the first wave especially with the newly

shown in Table 4. The death cases as percentages of the total number

discovered strains of the SARS‐Cov‐2 virus.

19

The present study

aimed to compare the severity and spread of the COVID‐19 different
waves using the available data of confirmed COVID‐19 cases and
death cases.

of confirmed cases in Wave 1 in all countries was much higher than
that in Waves 2, 3, and 4 as shown in Table 4.
The number of confirmed cases and death cases of the USA,
Italy, India, and UAE as a sample of the 12 selected countries were
presented in Figures 1 and 2, respectively. The results are split into
different waves; COVID‐19 Wave 1 data in blue color, COVID‐19

2
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Wave 2 data in red color, COVID‐19 Wave 3 data in green color, and
COVID‐19 Wave 4 data in black color. Table 2 and Figure 1 show

Data were collected for 12 countries (Italy, Brazil, Japan, Germany,

that Waves 2, 3, and 4 had much higher daily confirmed cases than

Spain, India, USA, UAE, Poland, Colombia, Turkey, and Switzerland) to

Wave 1. However, the death cases in Waves 2, 3, and 4 were com-

perform a comparative study between COVID‐19 pandemic waves.

parable with that of Wave 1 as shown in Table 3 and Figure 2.

To ascertain the consistency while separating the wave periods, we
tended to use the data of the highest number of deaths (the peak)
followed by the trough (the lowest number of cases and deaths). The

4 |
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data of all selected countries were separated into different main
periods called waves according to the number of waves in each

Although the globe is still learning from the first wave of the COVID‐

country.

19 outbreak, the second and the third waves of the epidemic have

The selected 12 countries were those with the highest total

surged. To the extent of our knowledge, this is the first study to

performed tests for SARS‐Cov‐2 detection in the world and their data

assess the discrepancy in severity and spread of the SARS‐CoV‐2

were available in the Center for Systems Science and Engineering

virus outbreak in the different waves in 12 different countries. Our

Italy

Brazil

Japan

Germany

Spain

India

USA

UAE

Poland

Colombia

Turkey

Switzerland

1

2

3

4

5

6

7

8

9

10

11

12

24/01/2020 to 26/11/2020

21/03/2020 to 13/08/2020

15/03/2020 to 29/09/2020

29/02/2020 to 01/12/2020

19/03/2020 to 24/11/2020

16/03/2020 to 06/09/2020

19/02/2020 to 01/09/2020

14/03/2020 to 15/10/2020

26/02/2020 to 31/07/2020

22/01/2020 to 29/09/2020

26/02/2020 to 22/09/2020

26/01/2020 to 21/06/2020

COVID_Wave_1 effective
period

Abbreviation: COVID‐19, coronavirus disease 2019.

Country

27/11/2021 to 24/07/2021

14/08/2020 to 16/03/2021

30/09/2020 to 24/07/2021

02/12/2020 to 24/07/2021

25/11/2020 to 18/03/2021

07/09/2020 to 14/02/2021

02/09/2020 to 22/01/2021

16/10/2020 to 22/02/2021

01/08/2020 to 18/01/2021

30/09/2020 to 22/02/2021

23/09/2020 to 1/02/2021

22/06/2020 to 01/11/2020

COVID_Wave_2 effective
period

Data cleaning and the effective period for each wave

No

TABLE 1

NA

17/03/2021 to 24/07/2021

NA

NA

19/03/2021 to 24/07/2021

15/02/2021 to 24/07/2021

23/01/2021 to 06/06/2021

23/02/2021 to 24/07/2021

19/01/2021 to 22/06/2021

23/02/2021 to 24/07/2021

02/02/2021 to 24/07/2021

02/11/2020 to 14/03/2021

COVID_Wave_3 effective
period

NA

NA

NA

NA

NA

NA

07/06/2021 to 24/07/2021

NA

23/06/2021 to 24/07/2021

NA

NA

15./03/2021 to 24/07/2021

COVID_Wave_4 effective
period

− Negative value (−2) on 09/08/2020 from
confirmed cases

− Negative value (−1) on 03/08/2020 from
confirmed cases

− Negative value (−104) on 21/05/2020 from
confirmed cases

− Negative value (−1) on 18/04/2020 from
confirmed cases

− Negative value (−31) on 09/10/2020 from
death cases

− Negative value (−1) on 06/06/2020 from
death cases

Removed data points
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T A B L E 2 Percentage of the total number of cases for the
different COVID‐19 waves in the confirmed cases

ET AL.

admission needs and short hospitalization stay. This claim was supported by the observed radiological consolidation associated with

Wave_3/
Wave_2 (%)

Wave_4/
Wave_3 (%)

pneumonia, which showed less severity index on the Brixia chest
pothesis, the fall in the fatality rate of COVID‐19 cases can be at-

No

Country

Wave_2/
Wave_1 (%)

1

Italy

473.24

409.94

121.30

2

Brazil

101.01

223.96

NA

3

Japan

83.44

276.19

NA

4

Germany

3224.71

186.70

20.38

ceive and take care of COVID‐19 patients.23,24 Moreover,

5

Spain

119.95

42.20

NA

polymerase chain reaction tests became readily available in the

6

India

260.58

162.85

43.33

7

USA

844.40

85.60

NA

months. Many countries applied treatment protocols that proved to

8

UAE

222.67

353.49

NA

be effective in most COVID‐19 cases with variable degrees of se-

9

Poland

61.74

NA

NA

verity. Additionally, the emerging of different vaccines could be a

10

Colombia

160.34

NA

NA

11

Turkey

2691.01

131.37

NA

in the second, third and, fourth waves are less severe than the first

12

Switzerland

2387.04

NA

NA

wave remains a challenging question that needs further assessment.

X‐ray scoring system in the second wave.21 In contrast to this hytributed to the early prediction of the second, third, and fourth
waves.22 Hence, most countries were timely prepared with protective measures; also, healthcare settings became more capable to re-

second, third, and fourth waves than the first one.25 Also, the clinical
management approaches enhanced significantly over the past few

reason for the lower confirmed cases in the third and the fourth
waves presented in our study.26 However, whether the viral infection

The spread of the infection in the second, third and, fourth

Abbreviation: COVID‐19, coronavirus disease 2019.

waves, and the numbers of cases that have been recorded till now
which markedly outweighed that of the first; can be explained in light
of the remerged B.1.1.7 variants of the virus which perhaps become
T A B L E 3 Percentage of the total number of cases for the
different COVID‐19 waves in the death cases

more infectious as reported in recent studies.27 However, the same
cannot be applied to the number of deaths, as the number of deaths
in the second wave has never been surpassed in most countries

No
Country

Wave_2/
Wave_1 (%)

Wave_3/
Wave_2 (%)

Wave_4/
Wave_3 (%)

1

Italy

85.98

831.02

93.49

2

Brazil

62.99

371.45

NA

3

Japan

52.44

194.33

NA

4

Germany

2499.03

139.63

3.85

over, the impact of vaccination was highly recognized especially in

5

Spain

123.95

86.96

NA

the fourth wave and the benefits were clear among healthcare

6

India

163.48

67.09

30.92

7

USA

783.60

130.59

NA

viruses because they have proofreading mechanisms during their

8

UAE

33.33

700.0

NA

replications.30,31 Also, until now, SARS‐CoV‐2 mutation diversity is

9

Poland

151.68

NA

NA

shallowly noted.32 So, any recorded mutation should be of interest

10 Colombia

72.50

NA

NA

11 Turkey

3611.11

674.46

NA

internalization, replication, and even immunological resistance.33 In

12 Switzerland

11128.57

NA

NA

particular, mutations that occur in genes encoding spike protein are

despite the higher number of confirmed cases in the waves that
follow.19,28 The decline in mortality and hospitalized severe cases can
be attributed to prompt diagnosis and isolation of suspected cases
with the availability of rapid antigen tests. In addition, better clinical
management and monitoring approaches became available. More-

workers and the elderly population.29 Naturally, coronaviruses are
not enduring many mutations or antigenic drift like that of influenza

Abbreviation: COVID‐19, coronavirus disease 2019.

and be paid attention, because it represents a natural selection that
can give favorable behaviors to its variant by enhancing viral fusion,

studied much because of the capability of such protein to enhance
host cell fusion, and entry, and it is chiefly the target of neutralizing
antibodies.34,35
Both SARS‐CoV‐2 and SARS‐CoV‐1 depend on angiotensin‐

findings showed that although there is an apparent huge increase in

converting enzyme 2 (ACE2) as their cellular receptor to establish cell

the number of confirmed cases in the second, third, and fourth waves

fusion, and they share about 79% sequence similarity.36 Depending

compared with the first one, the chances of survival have improved

on these similarities of both viruses in terms of their sequences and

very much as shown in the percentage of death presented here since

mode of internalizations, some fears could arise for any mutations in

most cases were less severe.

spike protein that could escort a different pool of neutralizing specific

Most of the reported cases in the second, third, and fourth waves

antibodies mediating the antibody‐dependent enhancement (ADE)

were mild to moderate based on clinical evidence with fewer hospital

infection. It was previously shown that some neutralizing antibodies

ZAWBAA
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T A B L E 4 Percentage of the total
number of death cases comparing with the
total number of confirmed cases for the
different COVID‐19 waves

No

Country

Wave_1
(%)

Wave_2
(%)

Wave_3
(%)

Wave_4
(%)

1

Italy

5.37

0.98

1.98

1.53

2

Brazil

3.01

1.88

3.11

NA

3

Japan

1.46

0.92

0.65

NA

4

Germany

4.60

3.57

2.67

0.50

5

Spain

6.10

6.30

12.98

NA

6

India

5.75

3.61

1.49

1.06

7

USA

2.08

1.93

2.95

NA

8

UAE

4.0

0.60

1.19

NA

9

Poland

0.17

0.42

NA

NA

10

Colombia

2.40

1.08

NA

NA

11

Turkey

0.62

0.83

4.26

NA

12

Switzerland

1.12

5.22

NA

NA

201

Abbreviation: COVID‐19, coronavirus disease 2019.

FIGURE 1
(D) UAE

Daily confirmed case in Wave 1 (blue), Wave 2 (red), Wave 3 (green), and Wave 4 (black) in (A) USA, (B) Italy, (C) India, and

against SARS‐CoV‐1 spike protein mediate antibody‐dependent en-

from A to G in the Wuhan original strain.33 These emerged mutations

hancement (ADE) in vitro and intensify disease in animal models.37–40

may result from natural selection or by chance, and the steady in-

The virus witnessed a change in the incorporated amino acid

crease of the G614 variant at regional stages could designate a fit-

sequence in the spike proteins that have the G614 early in the sec-

ness gain to this variant.28 This mutation increased the efficiency of

ond wave. These variants are now predominating in different places

the viral cell fusion to the host cell evidenced by cryoelectron mi-

globally versus the D614 that was firstly recognized in Wuhan, China,

croscopy (cryo‐EM).41,42 Therefore these variants have higher

with some panic about the possibility of this mutation affecting ADE.

transmission rates.19 It was reported that patients infected with the

The D614G amino acid indicates a change from aspartic acid (D) into

G614 variant of the second wave suffer from high upper respiratory

glycine (G) that is caused by a nucleotide mutation at position 23 403

tract viral load and shed more viral RNA during RT‐PCR analysis by

202
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FIGURE 2
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Daily death cases in Wave 1 (blue), Wave 2 (red), Wave 3 (green), and Wave 4 (black) in (A) USA, (B) Italy, (C) India, and (D) UAE

giving lower cycle thresholds (Cts) compared with those with D614,43
43

suggesting higher infectivity and rapid spreading.

than that in Wave 2. This could be due to the mutation found

Some in vitro

recently. Waves 3 and 4 had lower confirmed cases compared to that

models showed that the G614 variant displayed considerably higher

of Wave 2. That could be due to the presence of the appropriate

infectious titers (2.6–9.3 doubling rise) than the original D614.33

treatment and vaccination however, that was not reflected in the

Regarding the severity of second, third and, fourth waves' variants characterized by higher infectivity and rapid spreading, some

death cases, which were similar to Wave 2 in most countries. Further
studies are required to explain these findings.

reports showed no significant link between D614G mutation and
disease severity in terms of hospitalization outcomes.33 However, the

ACKNOWLEDGME NT S

noticed low recognized severity and mortality of the second, third

The researchers acknowledge the support given by Taif University

and, fourth waves could be attributed to the enhanced immunity

Researchers Supporting Project number (TURSP‐2020/50), Taif

against new variants due to their higher infectivity and titer that can

University, Taif, Saudi Arabia

influence the rapid activation of the adaptive immune system and
rapidly eradicate virus propagation and late fatal signs of COVID‐19

CONFLIC T OF INTERESTS

with no evidence of ADE. This is very distinguished from the original

The authors declare that there are no conflicts of interest.

reference SARS‐CoV‐2 at the first wave that gained a delayed
specific antibody response perceived amongst COVID‐19 patients

A UT H O R C O N T R I B U TI O NS

with severe progression.44 It was also showed that the D614G

Concept, Experiment, data entry, writing, data analysis, and interpreta-

variations would be likewise deactivated by a polyclonal antibody

tion: Hossam M. Zawbaa, Hasnaa Osama, Ahmed El‐Gendy, Haitham

that surprisingly demonstrated improved neutralization of a G614

Saeed, Hadeer S. Harb, Yasmin M. Madney, Mona Abdelrahman,

variant compared with a D614 counterpart.33

Marwa Mohsen, Mona Abdelrahman, Ahmed MA Ali, Mina Nicola,
Marwa O. Elgendy, and Ihab A. Ibrahim. Concept, planning of study
design, and reviewing the manuscript: Mohamed E. A. Abdelrahim.

5

| C ONC LUS I ON
DATA AVAILABILITY STATEMENT

In all the selected 12 countries, as a representative sample of the

The data sets analyzed during the current study are available from

whole world, COVID‐19 Wave 2 has much infectivity represented in

the corresponding author on reasonable request.

a higher number of confirmed cases compared to that in Wave 1.
However, the severity was much lower represented in the death

ORC I D

cases increase, which was not comparable to that of the confirmed

Hossam M. Zawbaa

cases to the extent that some countries had lower death cases than

Ahmed El‐Gendy

https://orcid.org/0000-0001-6548-2993
https://orcid.org/0000-0002-0980-5185

Wave 1 (UAE and Spain). The COVID‐19 death cases as a percentage

Haitham Saeed

https://orcid.org/0000-0002-2040-9466

of the total number of confirmed cases in Wave 1 were much higher

Hadeer S. Harb

https://orcid.org/0000-0003-2259-9686

ZAWBAA

|

ET AL.

Yasmin M. Madney

https://orcid.org/0000-0003-4105-7874

Mona Abdelrahman

https://orcid.org/0000-0002-8748-8090

Ahmed M. A. Ali

https://orcid.org/0000-0002-4370-007X

Mohamed E. A. Abdelrahim

19.

20.

https://orcid.org/0000-0003-

0227-8404
21.

REFERENCES
1.
2.

3.

4.

5.

6.

7.
8.

9.

10.

11.

12.

13.
14.
15.
16.

17.

18.

Saeed H, et al. COVID‐19; current situation and recommended interventions. Int J Clin Pract. 2020;75(5):e13886.
Elgendy MO, El‐Gendy AO, Abdelrahim MEA. Public awareness in
Egypt about COVID‐19 spread in the early phase of the pandemic.
Patient Educ Couns. 2020;103(12):2598‐2601.
Saeed H, Hemida A, El‐Nikhely N, et al. Highly efficient Pyrococcus
furiosus recombinant L‐asparaginase with no glutaminase activity:
expression, purification, functional characterization, and cytotoxicity
on THP‐1, A549 and Caco‐2 cell lines. Int J Biol Macromol. 2020;156:
812‐828.
Osama El‐Gendy A, Saeed H, Ali A, et al. Bacillus Calmette–Guérin
vaccine, antimalarial, age and gender relation to COVID‐19 spread
and mortality. Vaccine. 2020;38(35):p 5564‐5568.
Zawbaa H, El‐Gendy A, Saeed H, et al. A study of the possible
factors affecting COVID‐19 spread, severity and mortality and the
effect of social distancing on these factors: Machine learning forecasting model. Int J Clin Pract. 2021;75(6):e14116.
Chai S, Li Y, Li X, Tan J, Abdelrahim M, Xu X. Effect of age of COVID‐
19 inpatient on the severity of the disease: a meta‐analysis. Int J Clin
Pract. 2021:14640.
Fanelli D, Piazza F. Analysis and forecast of COVID‐19 spreading in
China, Italy and France. Chaos, Solitons Fractals. 2020;134:109761.
Elgendy MO, Abdelrahman MA, Osama H, El‐Gendy AO,
Abdelrahim MEA. Role of repeating quarantine instructions and
healthy practices on COVID‐19 patients and contacted persons to
raise their awareness and adherence to quarantine instructions. Int
J Clin Pract. 2021:e14694.
Elgendy MO, Elmawla MNA, Hamied AMA, Gendy SOE,
Abdelrahim MEA. COVID‐19 patients and contacted person
awareness about home quarantine instructions. Int J Clin Pract.
2020;75(4):e13810.
Sayed AM, Khalaf AM, Abdelrahim MEA, Elgendy MO. Repurposing
of some anti‐infective drugs for COVID‐19 treatment: A surveillance
study supported by an in silico investigation. Int J Clin Pract. 2020;
75(4):e13877.
He D, Zhao S, Li Y, et al. Comparing COVID‐19 and the 1918–19
influenza pandemics in the United Kingdom. Int J Infect Dis,
2020(98):67‐70.
Johnson NP, Mueller J. Updating the accounts: global mortality of
the 1918‐1920 "Spanish" influenza pandemic. Bull Hist Med. 2002;
76:105‐115.
Patterson KD, Pyle GF. The geography and mortality of the 1918
influenza pandemic. Bull Hist Med. 1991;65(1):4‐21.
Stevens KM. The pathophysiology of influenzal pneumonia in 1918.
Perspect Biol Med. 1981;25(1):115‐125.
Patterson KD. Pandemic influenza 1700‐1900: a study in historical
epidemiology. Rowman & Littlefield; 1986.
Laguarta J, Hueto F, Subirana B. COVID‐19 artificial intelligence
diagnosis using only cough recordings. IEEE Open J Eng Med Biol.
2020;1:275‐281.
Vaishya R, Javaid M, Khan IH, Haleem A. Artificial Intelligence (AI)
applications for COVID‐19 pandemic. Diabetes Metab Syndr: Clin Res
Rev. 2020;14(4):337‐339.
Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD.
How will country‐based mitigation measures influence the course of
the COVID‐19 epidemic? Lancet. 2020;395(10228):931‐934.

22.
23.
24.

25.

26.

27.
28.

29.
30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

203

Chen C‐Y, Chou Y‐C & Hsueh Y‐P SARS‐CoV‐2 D614 and G614
spike variants impair neuronal synapses and exhibit differential fusion ability. bioRxiv. Published online December 20, 2020.
COVID, global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU), ArcGIS. Johns
Hopkins CSSE. Accessed April 8, 2020
Borghesi A, Golemi S, Carapella N, Zigliani A, Farina D, Maroldi R.
Lombardy, Northern Italy: COVID‐19 second wave less severe than
the first? A preliminary investigation. Infect Dis (Lond). 2020;53(5):
370‐375.
Xu S, Li Y. Beware of the second wave of COVID‐19. Lancet. 2020;
395(10233):p 1321‐1322.
Cacciapaglia G, Cot C, Sannino F. Second wave COVID‐19 pandemics in Europe: a temporal playbook. Sci Rep. 2020;10(1):1‐8.
Leung GM, Leung K. First‐wave COVID‐19 transmissibility and severity in China outside Hubei after control measures, and second‐
wave scenario planning: a modelling impact assessment. Lancet.
2020;2:156.
Saito S, Asai Y, Matsunaga N, et al. First and second COVID‐19
waves in Japan: a comparison of disease severity and characteristics:
comparison of the two COVID‐19 waves in Japan. J Infect. 2020;82:
84‐123.
Elgendy MO & Abdelrahim MEA Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy. J Med Virol.
Published online July 20, 2021.
Soriano V, Fernandez‐Montero JV. New SARS‐CoV‐2 variants
challenge vaccines protection. ADIS Rev. 2021;23(1):57‐58.
Grubaugh ND, Hanage WP, Rasmussen AL. Making sense of mutation: what D614G means for the COVID‐19 pandemic remains unclear. Cell. 2020;182(4):794‐795.
Soriano V, de Mendoza C, Gómez‐Gallego F, Corral O, Barreiro P. Third
wave of COVID‐19 in Madrid, Spain. Int J Infect Dis. 2021;107:212‐214.
Sevajol M, Subissi L, Decroly E, Canard B, Imbert I. Insights into RNA
synthesis, capping, and proofreading mechanisms of SARS‐
coronavirus. Virus Res. 2014;194:90‐99.
Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal
mutagenesis: evidence for proofreading and potential therapeutics.
PLoS Pathog. 2013;9(8):e1003565.
Fauver JR, Petrone ME, Hodcroft EB, et al. Coast‐to‐coast spread of
SARS‐CoV‐2 during the early epidemic in the United States. Cell.
2020;181(5):990‐996.
Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in
SARS‐CoV‐2 spike: evidence that D614G increases infectivity of the
COVID‐19 virus. Cell. 2020;182(4):812‐827.
Chen WH, Hotez PJ, Bottazzi ME. Potential for developing a SARS‐
CoV receptor‐binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease
(COVID)−19. Hum Vaccin Immunother. 2020;16(6):1239‐1242
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in
the receptor binding domains of SARS‐CoV‐2 and SARS‐CoV.
Science. 2020;368(6491):630‐633.
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology
of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565‐574.
Jaume M, Yip MS, Cheung CY, et al. Anti‐severe acute respiratory
syndrome coronavirus spike antibodies trigger infection of human
immune cells via a pH‐and cysteine protease‐independent FcγR
pathway. J Virol. 2011;85(20):10582‐10597.
Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody‐
dependent enhancement of coronavirus entry. J Virol. 2020;94(5):
e02015‐19.
Wang SF, Tseng SP, Yen CH, et al. Antibody‐dependent SARS coronavirus infection is mediated by antibodies against spike proteins.
Biochem Biophys Res Commun. 2014;451(2):p 208‐214.

204

40.

41.

42.

43.

|
Yip MS, Leung HL, Li PH, et al. Antibody‐dependent enhancement of
SARS coronavirus infection and its role in the pathogenesis of SARS.
Hong Kong Med J. 2016;22(suppl 4):S25‐S31.
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D.
Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein. Cell. 2020;181(2):281‐292.
Wrapp D, Wang N, Corbett KS, et al. Cryo‐EM structure of the
2019‐nCoV spike in the prefusion conformation. Science. 2020;
367(6483):1260‐1263.
Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel
coronavirus (2019‐nCoV) by real‐time RT‐PCR. Euro Surveill. 2020;
25(3):2000045.

ZAWBAA

44.

ET AL.

Shen L, Wang C, Zhao J, et al. Delayed specific IgM antibody responses observed among COVID‐19 patients with severe progression. Emerg Microbes Infect. 2020;9(1):1096‐1101.

How to cite this article: Zawbaa HM, Osama H, El‐Gendy A,
et al. Effect of mutation and vaccination on spread, severity,
and mortality of COVID‐19 disease. J Med Virol. 2022;94:197‐
204. https://doi.org/10.1002/jmv.27293

